AFFiRiS AG Announces Management Changes

Founders Dr. Walter Schmidt and Dr. Frank Mattner to join the Supervisory Board

VIENNA, February 5, 2015 /PRNewswire/ --

AFFiRiS announces the appointment of Dr. Arne von Bonin as new member of the Executive Board. Dr. Walter Schmidt and Dr. Frank Mattner resign from their responsibilities in the Executive Board and will join the Supervisory Board.

Dr. Arne von Bonin (50) has been appointed member of the Executive Board and will, jointly with Oliver Siegel (49) who has been appointed as Chief Operating Officer in July 2014, form the Executive Board of AFFiRiS. Dr. Walter Schmidt and Dr. Frank Mattner, who founded the company eleven years ago, announced their resignation from the Executive Board and will join the Supervisory Board. Hon. Prof. Dr. Dietmar Czernich and Dr. Daniel Alge will resign from their positions in the Supervisory Board.

Michael Motschmann, Chairman of the Supervisory Board of AFFiRiS AG and member of the Executive Board of MIG Verwaltungs AG commented: "Dr. Walter Schmidt and Dr. Frank Mattner shaped the company ever since they founded it. We are grateful for their contributions in building a formidable organisation."

Dr. Arne von Bonin joined the company in 2012 as Head of Preclinical Development and Discovery. Previously, he was a member of the Supervisory Board of AFFiRiS AG. Before joining AFFiRiS, he held various positions in research of Schering AG and in R&D Management at Bayer Healthcare AG.

About AFFiRiS AG (By: February 2015):

On the basis of its proprietary patented AFFITOME®-technology, AFFiRiS develops tailor-made therapeutic peptide vaccines against chronic diseases. Currently, there are 3 drug candidates against Alzheimer's, Parkinson's and MSA in clinical development. Further vaccine candidates against Lipid Lowering respectively Atherosclerosis, Diabetes, Psoriasis, Allergies, Asthma as well as for Huntington's are in preclinical development. Thus far, AFFiRiS has been able to attract funding of close to € 100m, thereof ca. € 45m from license agreements. AFFiRiS currently employs 77 highly qualified staff at the Vienna Biocenter in Vienna, Austria.

Contact AFFiRiS AG:

Oliver Siegel
Karl-Farkas-Gasse 22
1030 Wien
T +43 (0)1/798-15-75-0
E [email protected]
W Distribution:

PR&D - Public Relations for Research & Education

Mariannengasse 8
1090 Vienna, Austria
T +43/(0)1/505-70-44
E [email protected]

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.